Some gene therapy treatments use modified adeno-associated viruses (AAVs) to deliver therapeutic genetic material into a patient's cells. These AAVs are engineered to target specific cell types.

Source: CRA analysis With growing eagerness to buy into the cell and gene therapy market, the fact that companies are targeting these drugs earlier in the development cycle is also driving them to ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing ... are highly efficient carriers for gene therapy. The LNPs facilitate RNA delivery ...

Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory ...

A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

In their latest study, a team led by Jonathan Cooper, Ph.D., professor of pediatrics at WashU Medicine, has shown that gene therapy ... the accumulated material inside the cells.

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely ...